Revolution Medicines
RVMD
200.87
+1.00
+0.50%
Revolution Medicines
US · RVMD
#499 by market cap
Listed 2020
200.87
+1.00
+0.50%
Live - 5344 symbols - heartbeat 514s ago
· 2026-10-08 07:27
Pre-market
198.00
-1.43%
After-hours
199.81
-0.53%
Overnight
199.95
-0.46%
- Market cap
- 43.05B
- P/E (TTM)i
- -22.65
- P/Bi
- 16.52
- EPSi
- -5.95
- Div yieldi
- 0.00%
- 52W posi
- 87%
Reader sentiment
Are you bullish or bearish on RVMD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 33.27, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Margins
Key ratios & quality
- Altman Z-Scorei
- 33.27
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 20.17M | 50.04M | 42.98M | 29.39M | 35.38M | 11.58M | 0 | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 9.41M | 12.41M | 21.43M | 30.45M | 40.59M | 75.62M | 97.30M | 195.04M |
| Research & development | 51.08M | 91.76M | 132.25M | 186.95M | 253.07M | 423.14M | 592.23M | 987.33M |
| Operating profit | -40.33M | -54.12M | -110.70M | -188.01M | -258.28M | -487.19M | -689.52M | -1.18B |
| Pretax profit | -41.79M | -52.04M | -108.53M | -187.09M | -249.13M | -439.89M | -600.85M | -1.13B |
| Tax | 0 | -4.37M | -371.00K | 0 | -420.00K | -3.52M | -753.00K | 0 |
| Net profit | -41.79M | -47.66M | -108.16M | -187.09M | -248.71M | -436.37M | -600.09M | -1.13B |
| Basic EPS | -1 | -1 | -2 | -3 | -3 | -4 | -4 | -6 |
| Diluted EPS | -1.34 | -1.17 | -2.01 | -2.57 | -3.08 | -3.86 | -3.58 | -5.95 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | 0 | 0 | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 35.01M | 40.58M | 52.76M | 66.68M | 101.25M | 110.21M |
| Research & development | 205.75M | 224.13M | 262.51M | 294.94M | 343.97M | 394.92M |
| Operating profit | -240.76M | -264.71M | -315.27M | -361.63M | -445.22M | -505.13M |
| Pretax profit | -213.42M | -247.79M | -305.21M | -364.89M | -453.82M | -644.37M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -213.42M | -247.79M | -305.21M | -364.89M | -453.82M | -644.37M |
| Basic EPS | -1 | -1 | -2 | -2 | -2 | -3 |
| Diluted EPS | -1.13 | -1.31 | -1.61 | -1.86 | -2.29 | -3.06 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 85.43M | 133.98M | 454.12M | 589.77M | 660.19M | 1.88B | 2.33B | 2.08B |
| Cash & ST investments | 69.59M | 122.76M | 440.74M | 577.05M | 644.94M | 1.85B | 2.29B | 2.03B |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 170.59M | 220.53M | 567.40M | 737.99M | 811.93M | 2.06B | 2.56B | 2.35B |
| Total current liabilities | 30.55M | 43.05M | 47.18M | 60.35M | 61.98M | 143.85M | 163.91M | 290.42M |
| Short-term debt | 147.00K | -- | 3.67M | 6.21M | 6.77M | 7.37M | 12.87M | 16.47M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 73,927,000.00 | 67,994,000.00 | 92,725,000.00 | 135,420,000.00 | 126,742,000.00 | 235,511,000.00 | 293,097,000.00 | 723,211,000.00 |
| Total equity | 96.66M | 152.54M | 474.68M | 602.57M | 685.19M | 1.83B | 2.27B | 1.63B |
| Retained earnings | -109.72M | -157.39M | -265.55M | -452.64M | -701.34M | -1.14B | -1.74B | -2.87B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 2.13B | 2.18B | 1.98B | 2.08B | 1.97B | 4.03B |
| Cash & ST investments | 2.10B | 2.14B | 1.93B | 2.03B | 1.91B | 3.94B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 2.37B | 2.43B | 2.25B | 2.35B | 2.25B | 4.32B |
| Total current liabilities | 158.60M | 184.53M | 245.62M | 290.42M | 289.60M | 354.06M |
| Short-term debt | 12.98M | 13.09M | 16.33M | 16.47M | 16.61M | 16.75M |
| Long-term debt | -- | -- | -- | -- | -- | 487.43M |
| Total liabilities | 287,203,000.00 | 564,199,000.00 | 655,016,000.00 | 723,211,000.00 | 753,820,000.00 | 1,717,032,000.00 |
| Total equity | 2.08B | 1.87B | 1.60B | 1.63B | 1.50B | 2.61B |
| Retained earnings | -1.95B | -2.20B | -2.50B | -2.87B | -3.32B | -3.97B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.21M | -49.62M | -100.06M | -147.18M | -224.40M | -350.57M | -557.44M | -897.74M |
| Depreciation & amortization | 1.76M | 3.34M | 6.55M | 7.33M | 9.66M | 9.31M | 11.82M | 16.56M |
| Free cash flow | -286.00K | -52.21M | -103.00M | -153.71M | -235.22M | -358.30M | -567.74M | -913.73M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 420.07M | 291.24M | 298.05M | 385.76M | 846.35M | 347.92M |
| Ending cash balance | 69.80M | 16.87M | 105.35M | 110.23M | 163.15M | 699.18M | 546.76M | 388.60M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -194.44M | -221.76M | -207.31M | -274.24M | -354.17M | -741.48M |
| Depreciation & amortization | 3.72M | 3.80M | 4.34M | 4.70M | 4.54M | 9.04M |
| Free cash flow | -197.70M | -229.21M | -210.66M | -276.16M | -355.70M | -745.31M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 347.92M | 226.73M | 1.88B |
| Ending cash balance | 337.25M | 406.35M | 222.30M | 388.60M | 445.80M | 820.29M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -274.12 | -- | -68.54 | -34.74 | -38.63 | -34.75 | -29.33 | -58.07 |
| ROA %i | -42.73 | -31.65 | -28.02 | -28.66 | -32.09 | -30.37 | -25.98 | -46.06 |
| ROIC %i | -275.89 | -- | -58.62 | -31.96 | -36.35 | -36.28 | -31.84 | -57.16 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -41.20 | -39.10 |
| EBIT margin %i | -206.66 | -103.78 | -252.33 | -636.54 | -704.14 | -3,796.10 | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.80 | 3.11 | 9.63 | 9.77 | 10.65 | 13.06 | 14.20 | 7.14 |
| Quick ratioi | 2.52 | 3.05 | 9.48 | 9.66 | 10.48 | 12.89 | 13.97 | 6.97 |
| Debt / assetsi | 0.09 | 0.00 | 5.76 | 9.03 | 7.91 | 4.27 | 5.31 | 6.74 |
| LT debt / equityi | -- | -- | 6.11 | 10.03 | 8.38 | 4.41 | 5.43 | 8.72 |
| Interest coveragei | -359.25 | -489.92 | -1,527.59 | -15,589.92 | -- | -1,450.79 | -- | -45.69 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 13.38 | -10.91 | -35.41 | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -36.68 | -46.61 | -60.76 | -58.07 | -76.67 | -79.09 |
| ROA %i | -32.64 | -38.32 | -47.87 | -46.06 | -59.39 | -52.37 |
| ROIC %i | -39.02 | -48.65 | -61.71 | -57.16 | -75.32 | -68.90 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 13.46 | 11.79 | 8.05 | 7.14 | 6.80 | 11.38 |
| Quick ratioi | 13.26 | 11.58 | 7.86 | 6.97 | 6.59 | 11.12 |
| Debt / assetsi | 5.68 | 5.47 | 7.04 | 6.74 | 6.95 | 14.85 |
| LT debt / equityi | 5.84 | 6.42 | 8.90 | 8.72 | 9.34 | 23.99 |
| Interest coveragei | -- | -- | -- | -45.69 | -- | -28.80 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Region
United States100.00%
Quote time 2026-10-08 07:27:19 · For reference only, not investment advice and not tailored to your situation.